Abstract MicroRNAs (miRNAs) are endogenous single-stranded non-coding RNAs of about ~ 22 nucleotides which suppress gene expression by selectively binding to the 3' non coding region (3'-UTR) of specific messenger RNAs through base-pairing. There are now more than 1600 human miRNAs annotated in the miRNA registry (http://microrna.sanger.ac.uk), but, at the moment, very few miRNAs have been well characterized and most of their roles remain unknown. miRNAs derive from transcripts that fold back on themselves to form distinctive hairpin structures, whereas the other types of endogenous small RNAs derive either from much longer hairpins that give rise to a greater diversity of small RNAs (siRNAs), or from bimolecular RNA duplexes (siRNAs), or from precursors without any suspected doublestranded character (piRNAs). The key step to understanding more about the possible functions of microRNA is to identify their mRNA targets. Recent studies have supported a role of miRNAs in the initiation and progression of human malignancies. Several groups have studied the global miRNA expression in cancer patients and found that miRNAs show different patterns of expression in normal and tumor tissues. The involvement of miRNAs in human cancer is probably due to the fact that >50% of miRNA genes are located at chromosomal regions, such as fragile sites or common break point sites, and regions of deletion or amplification that are generally altered in human tumors. Experimental evidence has shown that miRNA expression profiles enable the classification of poorly characterized human tumors that cannot be accurately classified using only the mRNA expression patterns. As a result, the miRs involved in the oncogenic transformation process are being investigated as novel biomarkers of disease detection and prognosis as well as potential therapeutic targets for human cancers. The aim of this review is to provide a general background regarding current knowledge about miRNA involvement in human pancreatic cancer and in the regulation of glucose metabolism.
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[ [17] [18] [19] , thus, these clustered miRnAs can be transcribed from a single polycistronic transcription unit. These clustered miRnAs may share functional relationships even if they have no apparent sequence homology. miRnAs are transcribed as long, poly-adenylated and capped primary transcripts (pri-miRnAs) that are cleaved, at nuclear level, to ~ 60-70 nucleotide hairpinshaped intermediates (pre-miRnAs) by the nuclear Rnase III Drosha [20] . Following nuclear processing by Drosha, premiRnAs are exported to the cytoplasm by the nuclear transport receptor exportin-5 [21] . It has been demonstrated that when cells are depleted of exportin-5, the pre-miRnA level and the mature miRnA level result to be reduced in the cytoplasm [21] .
At the cytoplasmic level pre-miRnAs are processed into ~ 22 nucleotide miRnA duplexes by the cytoplasmic Rnase III Dicer [22] . These double-stranded products are unwound by a still unidentified helicase and incorporated as single-stranded RnAs (guide strand) into a ribonucleoprotein complex, known as the RnA-induced silencing complex (RISc) [23] . Which strand is incorporated in the RISc is determined by the stability of the base pairs at the 5' end of the duplex. The incorporate guide strand guides the RISc to the complementary sequence in the 3'-UTR of target mRnA; the other strand is degraded (Figure 1 ). miRnAs mechanisms of action miRnAs can negatively regulate gene expression at the posttranscriptional level by targeting the 3'-UTR region of the expression in normal and tumor tissues [6] . Alteration of the expression of miRnAs has been demonstrated in human tumors such as colorectal neoplasia [7] , B cell chronic lymphocytic leukemia [8, 9] , B cell lymphoma [10] , lung cancer [11] , breast cancer [12] and glioblastoma [13, 14] . The involvement of miRnAs in human cancer is probably due to the fact that >50% of miRnA genes are located at chromosomal regions, such as fragile sites or common break point sites, and regions of deletion or amplification that are generally altered in human tumors [15] . Experimental evidence has shown that miRnA expression profiles enable the classification of poorly characterized human tumors that cannot be accurately classified by the mRnA expression patterns alone [16] . Therefore, miRnAs may reveal clinical benefits not only as targets for drug or gene therapies, but also as tools for cancer diagnosis. Krek et al. [33] demonstrated that the three most highly expressed miRnAs in the murine pancreatic cell lines, miR-124, miR-375, and let-7b, coordinately downregulated the expression of mtpn, and Plaisance et al. [34] found that the overexpression of miR-9, a miRnA selectively expressed in brain and pancreatic islets, caused a reduction of glucose-stimulated exocytosis and insulin release in insulin-secreting beta-cells. Increased levels of miR-9 are associated with increase in the level of Granuphilin/ Slp4, a protein that plays a strong negative modulatory role on insulin exocytosis. The effect of miR-9 on Slp4 expression is mediated by Onecut2 (Oc2), a transcription factor that exerts a repressive activity on Slp4 expression. Oc2 mRnA is a direct target of miR-9; the negative regulation of Oc2 translation by miR-9 results in an increased expression of Slp4 and, consequently, in a reduction of insulin release. In conclusion, miR-9 seems to be required to maintain an appropriate level of [24, 25] (Figure 1 ). In the first case, miRnA may act as small interfering RnAs (siRnAs) and cleave mRnA targets between the nucleotides pairing to positions 10 and 11 of the miRnA [26, 27] . After the cleavage of the target, the miRnA remains intact and can guide the recognition and destruction of other mRnAs [24] . miRnAs regulate glucose metabolism
The possible role of miRnAs in the regulation of hormone secretion the pancreas and in the development of tumors of the endocrine pancreas has been investigated in several studies during recent years.
To study the role of miRnAs in endocrine pancreas, Poy et al. [28] . 
miRnAs as Potential Biomarkers for Diabetes
Recently it has been shown that miRnAs could be detected in blood and other body fluids [37] [38] [39] [40] [41] . miRnAs are released in microvesicular structures, such as exosomes or apoptotic bodies, and circulate inside these membrane-delimited vesicles that protect them from degradation. circulating microvesicles seem to help cell-to-cell communication as well as exchange genetic information between healthy and injured cells and tissues [42, 43] .
microRnAs and pancreatic-endocrine system 
